Table 2

Meta-analysis for changes in other outcomes from baseline to the last available follow-up

ParameterNumber of patients (number of studies)Estimate (95% CI)*I2 (%)P value
Changes in patients using FGM
 Time in range (70–180 mg/dL) (hours/day)343 (3)0.55 (−0.17 to 1.26)480.14
 Time above 180 mg/dL (hours/day)343 (3)0.19 (−0.90 to 1.29)730.73
 Time below 70 mg/dL (hours/day)621 (4)−0.60 (−1.18 to −0.03)900.04
 Hypoglycemic events (n/day)597 (7)−0.04 (−0.23 to 0.15)910.67
 SMBG measurements (n/day)401 (5)−4.55 (−5.74 to −3.35)95<0.001
 Total daily insulin dose (IU/day)517 (6)−1.22 (−4.29 to 1.86)00.44
Differences in changes in patients using FGM versus patients using SMBG
 SMBG measurements (n/day)832 (4)−3.76 (−4.79 to −2.72)86<0.001
 Total daily insulin dose (IU/day)498 (3)0.23 (−1.34 to 1.80)00.77
 Discontinuation564 (3)0.42 (0.25 to 0.71)00.001
  • *Data are expressed as relative risk for discontinuation and as weighted mean differences for the other outcomes.

  • FGM, flash glucose monitoring; SMBG, self-monitoring of blood glucose.